This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
March 14, 2024
BONESUPPORT – CERAMENT® G RECEIVES FDA CLEARANCE FOR OPEN FRACTURES
March 13, 2024
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
March 13, 2024
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 13, 2024
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026
March 11, 2024
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
March 11, 2024
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 05, 2024
BONESUPPORT – CERAMENT® BONE VOID FILLER RECEIVES FDA CLEARANCE FOR SPINAL INTERBODY FUSION PROCEDURES
March 05, 2024
Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities
March 05, 2024
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 01, 2024
Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration